T. Rowe Price Associates
CCCC icon

T. Rowe Price Associates’s C4 Therapeutics CCCC Stock Holding History

T. Rowe Price Associates’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$728K Buy
155,881
+84,335
+118% +$288K ﹤0.01% 2456
2026
Q1 		$189K Buy
71,546
+59,146
+477% +$139K ﹤0.01% 2862
2025
Q4 		$24K Hold
12,400
– – ﹤0.01% 3075
2025
Q3 		$28K Hold
12,400
– – ﹤0.01% 3032
2025
Q2 		$18K Sell
12,400
-25,743
-67% -$37.4K ﹤0.01% 3048
2025
Q1 		$62K Hold
38,143
– – ﹤0.01% 2900
2024
Q4 		$138K Sell
38,143
-353,861
-90% -$1.76M ﹤0.01% 2783
2024
Q3 		$2.23M Buy
392,004
+329,697
+529% +$1.98M ﹤0.01% 1580
2024
Q2 		$288K Sell
62,307
-2,053,170
-97% -$12.2M ﹤0.01% 2437
2024
Q1 		$17.3M Sell
2,115,477
-443,003
-17% -$3.43M ﹤0.01% 1012
2023
Q4 		$14.5M Buy
2,558,480
+372,021
+17% +$848K ﹤0.01% 1025
2023
Q3 		$4.07M Sell
2,186,459
-642,146
-23% -$1.96M ﹤0.01% 1219
2023
Q2 		$7.78M Sell
2,828,605
-46,769
-2% -$150K ﹤0.01% 1108
2023
Q1 		$9.03M Sell
2,875,374
-49,879
-2% -$294K ﹤0.01% 1075
2022
Q4 		$17.3M Sell
2,925,253
-38,803
-1% -$322K ﹤0.01% 950
2022
Q3 		$26M Sell
2,964,056
-1,419,107
-32% -$14.7M ﹤0.01% 831
2022
Q2 		$33M Buy
4,383,163
+5,791
+0.1% +$51K ﹤0.01% 1013
2022
Q1 		$106M Buy
4,377,372
+292,574
+7% +$7.1M 0.01% 713
2021
Q4 		$132M Buy
4,084,798
+127,055
+3% +$5.02M 0.01% 680
2021
Q3 		$177M Buy
3,957,743
+412,906
+12% +$17.7M 0.02% 581
2021
Q2 		$134M Buy
3,544,837
+1,447,028
+69% +$51.8M 0.01% 682
2021
Q1 		$77.6M Buy
2,097,809
+567,767
+37% +$22.6M 0.01% 852
2020
Q4 		$49.4M Buy
+1,530,042
New +$44.4M 0.01% 970

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates's CCCC Position: Q2 2026 in Review

T. Rowe Price Associates increased its C4 Therapeutics (CCCC) stake by 118% in Q2 2026, buying an estimated $288K and bringing the position to 155,881 shares worth $728K. The position accounts for ﹤0.01% of the portfolio, ranked #2456.

T. Rowe Price Associates first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $177M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • T. Rowe Price Associates held 155,881 shares of C4 Therapeutics worth $728K as of Q2 2026.
  • T. Rowe Price Associates bought 84,335 C4 Therapeutics shares in Q2 2026, an estimated $288K.
  • C4 Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2456 holding.
  • T. Rowe Price Associates first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • T. Rowe Price Associates's C4 Therapeutics position peaked at $177M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.